Abivax (ADR)
Develops oral obefazimod for ulcerative colitis and Crohn's disease.
$113.67
After-hours close+0.35 (+0.31%)
At close$113.32(−0.86%)
Something off on this page? Send us feedback.
Breakdown13F · Form 4
Institutions 74.82%Insiders —
Shares outstanding 73.43M · Float 67.11M · 91.4% free float
Institutions13F, as of Jun 30, 2026
366 holders · 54.94M shares · 96 new positions · 190 increased · 105 reduced · 42 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| TCG Crossover Management, LLC | 6.01M | 8.18% | −473.3K | Aug 14, 2026 |
| Darwin Global Management, Ltd. | 3.62M | 4.93% | +152.9K | Aug 14, 2026 |
| Helikon Investments Ltd | 2.79M | 3.80% | +1.77M | Aug 11, 2026 |
| Vestal Point Capital, LP | 2.35M | 3.20% | +849.4K | Aug 14, 2026 |
| Jupiter Topco LLC | 1.91M | 2.61% | +1.91Mnew | Aug 14, 2026 |
| UBS Group AG | 1.84M | 2.51% | −2.70M | Aug 13, 2026 |
| Adar1 Capital Management, LLC | 1.80M | 2.46% | +410.7K | Aug 14, 2026 |
| Caligan Partners LP | 1.56M | 2.12% | +96.0K | Aug 14, 2026 |
Beneficial owners13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| TCG Crossover GP I, LLC | 8.30% | 6.46M | 13G | Nov 14, 2025 ↗ |
| Invus Public Equities, L.P. | 5.00% | 3.92M | 13G | Feb 13, 2026 ↗ |
InsidersForm 4
Latest trades
Nothing filed in the last 12 months.
CongressHouse and Senate disclosures
Not reported.